Determination of the immune response type in measles patients of different ages from a high-incidence area

封面

如何引用文章

全文:

详细

According to the WHO data, the incidence of measles is now in the cyclic increase phase. The non-vaccinated subjects, like as persons who have previously received one or two doses of measles vaccine are involved in the epidemic process. The purpose of our study was to determine the immunological pattern in the groups of measles patients of different age in areas with high incidence of infection. To determine the immune response type in measles patients, qualitative and quantitative indices of IgM and IgG were used, detected by the following ELISA test-systems: VectoMeasles-IgM (JSC “Vector-Best”, Russia); Anti-Measles Viruses ELISA (IgG) and Avidity Anti-Measles Viruses ELISA IgG (Euroimmun, Germany). The serological study of 1893 patient allowed to determine the primary and secondary types of immune response. In 72.64% of the patients with primary immune response, the serum samples contained low-avidity IgG at a concentration of 0.45 (0.22- 0.74) IU/mL. In the group with a secondary immune response, high-avidity antibodies were detected at a concentration of 24.28 (21.59-27.4) IU/mL. The antibody levels in secondary type of response was 54-fold higher than IgG values in the first group (p < 0.05). In the group with primary immune response, the ratio of children (< 1 to 14 years) and adults (18 to 70 years old) was almost the same (49.6% and 47.56%). Appropriate values for children and adult cohorts with a secondary immune response were 2.12% and 96.53%, respectively (p < 0.05). Among 46 teenagers (15-17 years old), 84.8% responded with a primary immune response to the measles virus. Thus, in the area with high-incidence of measles among patients of different age, the primary-type immune response was determined in 72.64%, and secondary-type, in 27.36%. We have found that in the patients with a secondary type of immune response group, the proportion of children and teenagers was 27.8 times lower than among adults, thus indicating to high efficiency of vaccination in pediatric population. At the same time, the results of studies among measles patients with primary-type immune response, both children and adults, suggest some “gaps” in the vaccine prevention program.

作者简介

T. Mamaeva

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology

Email: 4522826@bk.ru

PhD (Biology), Leading Research Associate, Laboratory of Applied Immunochemistry

俄罗斯联邦, Moscow

T. Rubalskaya

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology

Email: rubalskaia@yandex.ru

Head, Laboratory of Applied Immunochemistry

俄罗斯联邦, Moscow

P. Zherdeva

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology

Email: polya-zherdeva@mail.ru

Research Associate, Laboratory of Applied Immunochemistry

俄罗斯联邦, Moscow

V. Metelskaya

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology

Email: pevek.1972@mail.ru

PhD (Biology), Senior Research Associate, Acting Head, Laboratory of Applied Immunochemistry

俄罗斯联邦, Moscow

Anna Toptygina

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology; Lomonosov Moscow State University

编辑信件的主要联系方式.
Email: toptyginaanna@rambler.ru

PhD, MD (Medicine), Chief Research Associate, Head, Laboratory of Cytokines, G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology; Professor, Department of Immunology, Faculty of Biology, Lomonosov Moscow State University

俄罗斯联邦, Moscow; Moscow

参考

  1. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году» https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=14933. [Электронный ресурс]. Режим доступа: https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=14933. [State report «On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2019». [Electronic resourse]. Access mode: https://www.rospotrebnadzor.ru/ documents/details.php?ELEMENT_ID=14933.
  2. Мамаева Т.А., Железнова Н.В., Бичурина М.А., Наумова М.А., Говорухина М.В., Топтыгина А.П. Оценка возрастной структуры больных корью с первичным и вторичным иммунным ответом за период 2010-2016 годы в Российской Федерации // Инфекция и иммунитет, 2020. Т. 10, № 4. С. 717-728. [Mamaeva T.A., Zheleznova N.V., Bichurina M.A., Naumova M.A., Govoruhina M.V., Toptygina A.P. Evaluation of age-related distribution of measles cases with primary and secondary immune response in Russian Federation, 2010-2016. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2020, Vol. 10, no. 4, pp. 717-728. (In Russ.)] doi: 10.15789/2220-7619-EOA-1407.
  3. Мамаева Т.А., Железнова Н.В., Наумова М.А., Говорухина М.В., Калашникова Н.А., Бичурина М.А., Мукомолов С.Л. Алгоритм лабораторного подтверждения и дифференциальной диагностики коревой инфекции в период элиминации кори в Российской Федерации // Инфекция и иммунитет, 2015. T. 5, № 1. C. 55-62. [Mamaeva Т.А., Zheleznova N.V., Nаumova М.А., Govoruhina M.V., Kalashnikova N.A., Bichurina M.A., Mukomolov S.L. Algorithm of laboratory confirmation and differential diagnosis of measles infection at the stage of the measles elimination program in Russia. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2015, Vol. 5, no. 1, pp. 55-62. (In Russ.)] doi: 10.15789/2220-7619-2015-1-55-62.
  4. Мамаева Т.А., Наумова М.А,, Железнова Н.В., Липская Г.Ю., Mulders М., Featherstone D.A. Оценка коммерческих тест-систем ИФА разного формата для определения уровня специфических IgM и IgG в сыворотках больных корью // Вопросы вирусологии, 2013. T. 58, № 5. C. 43-48. [Mamaeva Т.А., Naumova М.А., Zheleznova N.V., Lipskaya G.Y., Mulders М., Featherstone D.A. Estimation of the commercial ELIZA test-systems of different formats to detect specific IgM and IgG in the measles patients sera. Voprosy virusologii = Problems of Virology, 2013, Vol. 58, no. 5, pp. 43-48. (In Russ.)]
  5. СанПиН 3.3686-21 «Санитарно-эпидемиологические требования по профилактике инфекционных болезней». URL: http://publication.pravo.gov.ru/Document/View/0001202102180019. [SanPiN 3.3686-21 «Sanitary and epidemiological requirements for the prevention of infectious diseases». (In Russ.)]
  6. Топтыгина А.П., Мамаева Т.А. Динамика синтеза и циркуляции субклассов специфических IgG при иммунном ответе на вакцину против кори, краснухи, эпидемического паротита // Российский иммунологический журнал, 2019. T. 13, № 1. C. 78-85. Toptygina A.P., Mamaeva T.A. Analyzing features of measles immune response in adult patients. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2019, Vol. 13, no. 1, pp. 78-85. (In Russ.)] doi: 10.31857/S102872210005024-1.
  7. Топтыгина А.П. Смердова М.А. Наумова М.А. Владимирова Н.П., Мамаева Т.А. Влияние особенностей популяционного иммунитета на структуру заболеваемости корью и краснухой // Инфекция и иммунитет, 2018. Т. 8, № 3. С. 341-348. [Toptygina A.P., Smerdova M.A., Naumova M.A., Vladimirova N.P., Mamaeva T.A. Influence of population immunity peculiarities on the structure of measles and rubella prevalence. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2018, Vol. 8, no. 3, pp. 341-348. (In Russ.)] doi: 10.15789/2220-7619-2018-3-341-348.
  8. Цвиркун О.В., Тихонова Н.Т., Тураева Н.В., Ежлова Е.Б., Мельникова А.А., Герасимова А.Г. Характеристика популяционного иммунитета к кори в Российской Федерации // Эпидемиология и вакцинопрофилактика, 2020. T. 19, № 4. C. 6-13. [Tsvirkun O.V., Tikhonova N.T., Turaeva N.T., Ezhlova E.B., Melnikova A.A., Gerasimova A.G. Population immunity and structure of measles cases in the Russian Federation. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention, 2020, Vol. 19, no. 4, pp. 6-13. (In Russ.)]
  9. Chen R.T., Markowitz L.E., Albrect P., Stewart J.A., Mofenson L.M., Preblud S.R., Orenstein W.A. Measles antibody: reevaluation of protective titers. J. Infect. Dis., 1990, Vol. 162, no. 5, pp. 1036-1042.
  10. Cherry J.D., Zahn M. Clinical Characteristics of measles in previously vaccinated and unvaccinated patients in California. Clin. Infect. Dis., 2018, Vol. 67, no. 9, pp. 1315-1319.
  11. Damien B., Huiss S., Schneider F., Muller C.P. Estimated susceptibility to asymptomatic secondary immune response against measles in late convalescent and vaccinated persons. J. Med. Virol., 1998, Vol. 56, pp. 85-90.
  12. Durrhem D.N. Measles virus is unforgiving where immunity gaps exist. J. Infect. Dis., 2017, Vol. 216, no. 10, pp. 1183-1184.
  13. Durrhem D.N., Crowcroft N.S. The price of delaying measles eradication. Lancet Public Health, 2017, Vol. 2, no. 3, pp. e130-e131
  14. Griffin D.E. The immune response in measles: virus control, clearance and protective immunity. Viruses, 2016, Vol. 8, no. 10, 282. doi: 10.3390/v8100282.
  15. Hahn S.J.M., Nic Lochlainn L.M., van Burgel N.D. Measles outbreak among previously immunized healthcare workers, The Netherlands, 2014. J. Infect. Dis., 2016, Vol. 214, no. 12, pp. 1980-1986.
  16. Hübschen J.M., Bork S.M., Brown K.E., Mankertz A., Santibanez S., Ben Mamou M., Mulders M.N., Muller C.P. Challenges of measles and rubella laboratory diagnostic in the era of elimination. Clin. Microbiol. Infect., 2017, Vol. 23, pp. 511-515.
  17. Hübschen J.M., Gouandjika-Vasilache I., Dina J. Measles. Lancet. 2022, Vol. 399, pp. 678-690.
  18. Javelle E., Colson P., Parola P., Raoult D. Measles, the need for a paradigm shift. Eur. J. Epidemiol., 2019, Vol. 34, no. 10, pp. 897-915.
  19. Kang J.H. Febrile illness with skin rashes. Infect. Chemother, 2015, Vol. 47, pp. 155-166
  20. Komabayashi K., Seto J., Tanaka S. The largest measles outbreak, including 38 modified measles and 22 typical measles cases in its elimination Era in Yamagata, Japan, 2017. Jap. J. Infect. Dis., 2018, Vol. 71, no. 6, pp. 413-418.
  21. Kontio M., Jokinen S., Paunio M., Peltola H., Davidkin I. Waning Antibody Levels and Avidity: Implications for MMR Vaccine-Induced Protection. J. Infect. Dis., 2012, Vol. 206, no. 10, pp.1542-1548.
  22. Manual for the Laboratory-based Surveillance of Measles, Rubella, and Congenital Rubella Syndrome. Third edition, June 2018. Available at: https://www.who.int/publications/m/item/chapter-1-manual-for-the-laboratory-based-surveillance-of-measles-rubella-and-congenital-rubella-syndrome.
  23. Measles and rubella monthly update – WHO European Region – November 2023. Available at: https://www.who.int/europe/publications/m/item/measles-and-rubella-monthly-update-who-european-region-november-2023.
  24. Measles and rubella strategic framework: 2021-2030. World Health Organization. 2020. Available at: https://iris.who.int/handle/10665/339801.
  25. McKee A., Ferrari M.J., Shea K. Correlation between measles vaccine doses: implications for the maintenance of elimination. Epidemiol. Infect., 2018, Vol. 146, pp. 468-475
  26. Rota P.A., Moss W.J., Takeda M., de Swart R.L., Thompson K.M., Goodson J.L. Measles. Nat. Rev. Dis. Primers, 2016, Vol. 2, 16049. doi: 10.1038/nrdp.2016.49.
  27. Sowers S.B., Rota J.S., Hickman C.J., Mercader S., Redd S., McNall R.J. High concentrations of measles neutralizing antibodies and high-avidity measles IgG accurately identify measles reinfection cases. Clin. Vaccine Immunol., 2016, Vol. 23, no. 8, pp. 707-716.
  28. WHO epidemiological report. Regional Office for Europe of the World Health Organization, 2020, Vol. 1, pp. 1-13. Available at: https://www.euro.who.int/__data/assets/pdf_file/0006/434364/EpiBrief-1-2020-rus.pdf".
  29. Woods C.R. False-positive results for immunoglobulin M serologic results: explanations and examples. J. Pediatric Infect. Dis. Soc., 2013, Vol. 2, no. 1, pp. 87-90.
  30. Zhang Z., Chen M., Ma R., Pan J., Suo L., Lu L. Outbreak of measles among persons with secondary vaccine failure, China, 2018. Hum. Vaccin. Immunother., 2020, Vol. 16, no. 2, pp. 358-361.

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure 1. Age structure of patients with measles

下载 (186KB)
索引源数据
3. Figure 2. Immunological map of patients with measles of different ages: 1, group of primary immune response; 2, group of secondary immune response

下载 (162KB)
索引源数据

版权所有 © Мамаева Т., Рубальская Т., Жердева П., Метельская В., Топтыгина А., 2024

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##